Loading
Life sciences · Journal article
Journal of Medicinal Chemistry · August 13, 2026
Raises a question worth testing. It does not answer one.
This is an in vitro mechanistic study presenting novel bifunctional ionophores (HDQ variants) designed to simultaneously activate copper toxicity and disrupt iron–sulfur protein homeostasis in cancer cells. The compounds show copper transport and trigger cuproptosis-related cellular endpoints in cell culture, but the abstract provides no quantitative efficacy data, in vivo validation, or comparison of the lead compound (HDQ) against the clinical reference elesclomol.
In vitro chemical design and cellular mechanism study. Cancer cells in culture. Intervention: Bifunctional ionophores (HDQ, HDQ-S, HDQ-Ph, HDQ-Me) designed to coordinate copper and inhibit Fe–S protein homeostasis. Compared with: Elesclomol (clinical copper ionophore) and bacterial SUF inhibitor (inspiration for design).
HDQ-Me achieves efficacy comparable to clinical copper ionophore elesclomol in copper transport into cancer cells HDQ alone suppresses Fe–S proteins across multiple cellular functions including respiration, iron homeostasis, and DNA replication HDQ-mediated copper loading triggers cuproptosis hallmarks, DNA damage, and ATP collapse with synergistic lethality
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Early-stage in vitro mechanistic work demonstrating a novel compound design principle and cellular effects in cancer cells, without clinical trial data or in vivo efficacy validation.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Cellular resilience to therapy often arises from adaptive mechanisms that safeguard iron–sulfur (Fe–S) proteins. Here, we present a rational strategy to overcome such resilience by integrating two synergistic vulnerabilities, copper toxicity and Fe–S cluster homeostasis, into a single molecular scaffold. Inspired by a bacterial sulfur mobilization (SUF) inhibitor, we hybridized its core structure with a copper-transporting 8-hydroxyquinoline moiety to generate HDQ, HDQ-S, HDQ-Ph, and HDQ-Me. They coordinate copper via hydroxyquinoline and efficiently transport copper into cancer cells, with HDQ-Me achieving an efficacy comparable to that of the clinical copper ionophore elesclomol (ES). Strikingly, HDQ alone suppresses Fe–S proteins across multiple functions, including respiration, iron homeostasis, and DNA replication. HDQ-mediated copper loading triggers cuproptosis hallmarks, DNA damage, and ATP collapse, generating a synergistic lethality. This work establishes HDQs as bifunctional tools that cotarget copper and Fe–S protein homeostasis, validating a convergent therapeutic strategy against resilient cells.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.